US Stock MarketDetailed Quotes

NAMS NewAmsterdam Pharma

Watchlist
  • 21.990
  • +0.550+2.57%
Close Apr 26 16:00 ET
  • 21.850
  • -0.140-0.64%
Post 18:25 ET
1.96BMarket Cap-10227P/E (TTM)

NewAmsterdam Pharma Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

NewAmsterdam Pharma Earnings Date

Currency: USD

Period

FY2023 Annual Report

--

Revenue(YoY)

14.09M

-86.28%
EPS(YoY)

-2.15

-80.67%
Analyst Rating

Strong Buy

Apr 18, 2024

NewAmsterdam Pharma Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 7 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: EUR

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2024/Q2-- / 1.303M--
--2024/Q1-- / 1.607M--
--2023/Q4-- / 1.767M--
--2023/Q2-- / 1.950M--
--2023/Q1-- / 1.467M--
--2022/Q4-- / 1.750M--
--2022/Q3-- / 3.500M--
DatePeriodRevenue/EstimateEarnings Call
--2024/Q2-- / 1.303M--
--2024/Q1-- / 1.607M--
--2023/Q4-- / 1.767M--
--2023/Q2-- / 1.950M--
--2023/Q1-- / 1.467M--
--2022/Q4-- / 1.750M--
--2022/Q3-- / 3.500M--
--------
--------
--------

Unlock Free Earnings Estimates

NewAmsterdam Pharma Earnings Reports

  • NewAmsterdam Pharma | 10-K: Annual report

    Feb 28 08:02 ET

  • NewAmsterdam Pharma | 6-K: Report of foreign private issuer (related to financial reporting)

    Aug 7, 2023 07:24 ET

  • NewAmsterdam Pharma | 6-K: Report of foreign private issuer (related to financial reporting)

    Jun 9, 2023 21:39 ET

  • NewAmsterdam Pharma | 20-F: Registration statement / Annual report / Transition report

    Mar 31, 2023 16:31 ET

    • Read more

    Analysis

    Analyst Rating

    Updated: Apr 18, 2024

    Strong Buy

    • Buy

      100.00%

    • Hold

      0.00%

    • Sell

      0.00%

    Price Target

    No Data

    Heat List
    US
    Overall
    Symbol
    Latest Price
    %Chg